Waikoloa, Hawaii - A new foam formulation of the antifungal drug ketoconazole (Extina 2 percent, Connetics Corp.), currently under FDA review, seems to be more completely absorbed into the skin than the same ingredient in other formulations and could be more effective in the treatment of sehorrheic dermatitis, said Linda F. Stein Gold, M.D., director of clinical research, department of dermatology, Henry Ford Health System, West Bloomfield, Mich.
FDA implements updated iPLEDGE REMS requirements for isotretinoin, allowing at-home pregnancy testing and reducing prescription and counseling burdens.
Recent dermatology research explores chronic hand eczema prevalence, cancer risk in morphea, pernio, biologic optimization in HS, and melanoma risk prediction.
A pediatric dermatologist explains how CALM count, size, age, and associated findings separate benign spots from neurofibromatosis type 1 and its mimics.